Head-to-head evidence
DA-1726 vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
DA-1726
Developed by MetaVia
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06252220 (registry estimate)
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06077864 · Phase 3 · completed
The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.
Next expected readout: December 2026 · NCT07768813 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-1726's landscape · survodutide's landscape